問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kuang Tien General Hospital (在職)

Division of Urology

Division of Hematology & Oncology

童綜合醫療社團法人童綜合醫院

Division of Hematology & Oncology

Division of Urology

更新時間：2023-09-19

李毅彥
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

9Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李毅彥

Kuang Tien General Hospital

Division of Urology

List

6Cases

2019-07-22 - 2026-12-29

Phase III

Active
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy

  • Condition/Disease

    Advanced Prostate Cancer

  • Test Drug

    Apalutamide (JNJ-56021927)

Participate Sites
7Sites

Recruiting7Sites

2020-10-26 - 2028-06-30

Phase III

Active
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

  • Condition/Disease

    Metastatic Castration-Sensitive Prostate Cancer

  • Test Drug

    Niraparib

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting1Sites

Terminated7Sites

2022-09-01 - 2026-08-31

Phase IV

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2017-11-01 - 2022-12-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2017-11-01 - 2022-12-31

Phase I/II

A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with Locally Advanced or Metastatic Urothelial Cell Carcinoma who have Relapsed After, or are Refractory to Standard Therapy.

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cell Carcinoma

  • Test Drug

    Vofatamab (B-701)

Participate Sites
9Sites

Terminated8Sites

蘇柏榮
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2019-03-01 - 2021-02-28

Phase I

An Openlabel, Pilot Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of a Single Dose of Oradoxel in Metastatic Prostate Cancer Patients Treated With Intravenou s Docetaxel

  • Condition/Disease

    Metastatic Prostate Cancer

  • Test Drug

    Oradoxel (Docetaxel + HM30181)

Participate Sites
3Sites

Recruiting3Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB